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Cisplatin causes nephropathy accompanied by two types of cell death, necrosis and apoptosis, according to its dosage. The mechanisms of
necrosis are still unclear. In this study, we examined how high doses of cisplatin induce cell injury and whether a high affinity sodium-dependent
glucose transporter (SGLT1) has a cytoprotective function in renal epithelial LLC-PK1 cells. Cisplatin decreased in transepithelial electrical
resistance (TER) and increased in the number of necrotic dead cells in a time dependent manner. Phloridzin, a potent SGLT1 inhibitor, enhanced
both TER decrease and increase of necrotic dead cells caused by cisplatin. Cisplatin increased in the intracellular nitric oxide, superoxide anion
and peroxynitrite productions. Phloridzin enhanced the peroxynitrite production caused by cisplatin. The intracellular diffusion of ZO-1 and TER
decrease caused by cisplatin were inhibited by N-nitro-l-arginine methyl ester, a nitric oxide synthase inhibitor. Protein kinase C was not involved
in the cisplatin-induced injury. 5,10,15,20-tetrakis-(4-sulfonatophenyl)-porphyrinato iron (III) and reduced glutathione, peroxynitrite scavengers,
inhibited the cisplatin-induced ZO-1 diffusion, TER decrease, and increase of necrotic dead cells. These results suggest that peroxynitrite is a key
mediator in the nephrotoxicity caused by high doses of cisplatin. SGLT1 endogenously carries out the cytoprotective function by the reduction of
peroxynitrite production.
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Cisplatin and its analogs of platinum complexes are effec-
tive chemotherapeutic agents against a variety of solid tumors
of the ovary, testis, bladder, head and neck, cervix, and lung.
However, its use is often limited due to its adverse effects such
as nephrotoxicity, leading to acute renal failure and the0005-2736/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
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Abbreviations: AMG, Methyl a-glucopyranoside; eNOS, endothelial nitric
oxide synthase; FeTPPS, 5,10,15,20-tetrakis-(4-sulfonatophenyl)-porphyrinato
iron (III); GSH, reduced glutathione; l-NAME, N-nitro-l-arginine methyl
ester; OCTs, organic cation transporters; PI, propidium iodide; PKC, protein
kinase C; PMA, phorbol 12-myristate 13-acetate; RNS, reactive nitrogen
species; ROS, reactive oxygen species; TER, transepithelial electrical
resistance; TJ, tight junction; ZO, zonula occludens
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E-mail address: ikari@u-shizuoka-ken.ac.jp (A. Ikari).long-term impairment of renal function [1,2]. The nephrotoxic
effect of cisplatin is characterized by definitive histological
changes and is primarily found in the S3 segment of the
proximal tubule [3,4]. Cisplatin nephrotoxicity is associated
with increases in reactive oxygen species (ROS) and reactive
nitrogen species (RNS) such as superoxide anion, hydroxyl
radical, and peroxynitrite [5,6]. In cisplatin chemotherapy, it is
clinically important to arrest the development of nephrotoxi-
city, but effective therapeutic or prophylactic agents have not
yet been found.
Studies on animals have established that tubular injury plays
a central role in the reduction of the glomerular filtration rate in
acute tubular necrosis. A number of studies have shown that
cisplatin induces apoptosis or necrosis in renal tubular
epithelial cells in vivo and in vitro, depending on the
concentration and exposure time [7–9]: Apoptosis is induced
by exposure to low concentrations of cisplatin (<50 AM) for a
long time (<12 h), whereas necrosis is elicited by transient1717 (2005) 109 – 117
http://www
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ROS generation, cytochrome c release from mitochondria, and
caspase activation are involved in cisplatin-induced apoptosis
[5,10,11]. Furthermore, protein kinase C (PKC) is implicated in
cisplatin-induced caspase activation and apoptotic cell death
[12,13]. In contrast, the cellular mechanisms underlying
cisplatin-induced necrosis are not fully understood.
Four types of sodium-dependent glucose transporter family
have been cloned, SGLT1, SGLT2, SGLT3, and NaGLT1.
SGLT2 and NaGLT1 are expressed in the luminal membrane of
the S1 segment and reabsorb the most filtered glucose. In
contrast, SGLT1 is exclusively expressed in the S3 segment
and reabsorbs the remaining glucose not reabsorbed in the early
proximal tubule [14]. Besides glucose reabsorption, diverse
physiological roles were found for the SGLT family: human
SGLT1 functions as a water channel [15] and human SGLT3
functions as a glucose-sensitive sodium channel [16]. We
recently found that SGLT1 is involved in the repair of plasma
membrane integrity and tight junction (TJ) integrity injured by
heat stress [17,18]. Interestingly, the diabetic state attenuates
cisplatin nephrotoxicity in streptozotocin-induced diabetic rats
[19]. In this rat model, the expression and glucose transport of
SGLT1 are enhanced compared with control rats [20]. These
reports assume that SGLT1 has a cytoprotective function
against cisplatin injury.
The defining characteristics of epithelia include their ability
to create selective barriers between tissue spaces and to
generate polarity of the cellular structure and function. The
most apical intercellular junction, the TJ, regulates barrier
function by conferring size selectivity over paracellular
transport. Many diseases of the kidney, such as ischemia/
reperfusion or toxic injury, are closely related to the loss of the
epithelial barrier [21,22]. This study was undertaken to
examine the involvements of ROS and RNS in cisplatin-
induced acute cell injury in renal proximal tubular epithelial
cells. To determine cell injury, we measured transepithelial
electrical resistance (TER), which is an easy functional
parameter to monitor for epithelial monolayer integrity.
Furthermore, we evaluated the effect of phloridzin, a potent
SGLT1 inhibitor, on the TJ integrity, ROS and RNS genera-
tions and the cell death caused by cisplatin to determine the
cytoprotective function of SGLT1.
2. Materials and methods
2.1. Cell Culture
Porcine renal epithelial LLC-PK1 cells were obtained from JCRB (Tokyo,
Japan). Cells were maintained in a humidified incubator at 37 -C in a 5% CO2
atmosphere in Medium 199 (Sigma) supplemented with 10% fetal calf serum
(FCS), 0.07 mg/ml penicillin G and 0.14 mg/ml streptomycin sulfate. The
media contain 5.6 mM glucose. Cells were cultured for 24 h in the media
without FCS before the experiments.
2.2. Measurement of TER
LLC-PK1 cells were grown to confluent densities in a Transwell chamber
(24-well plate, Corning Life Sciences, Acton, MA). TER was measured three
times per well at indicated periods using a Millicell-ERS epithelial volt-ohmmeter (Millipore, Bedford, MA) and averaged values were collected. TER
values (ohmscm2) were normalized by the area of the monolayer and
calculated by subtracting the blank values from the filter and the bathing
medium.
2.3. Measurement of necrotic and apoptotic dead cells
Cells were grown to sub-confluent and confluent densities on 35-mm glass-
bottom culture dishes. The number of necrotic dead cells was measured using
an annexin V-FITC apoptosis detection kit (Sigma, St. Louis, MO). The cells
were incubated with cisplatin for indicated periods, and then incubated with
annexin V-FITC and propidium iodide (PI) for 10 min at room temperature.
Cells were washed twice with a binding buffer and visualized on an LSM 510
confocal laser microscope (Carl Zeiss, Germany) set with the appropriate filter
for FITC (488 nm excitation and 505–530 nm emission filter) and PI detection
(543 nm excitation and 650 nm emission filter). PI can penetrate into necrotic
or late apoptotic cells, but not viable or early apoptotic cells, whereas in
annexin V, a protein with high affinity for phosphatidylserine, can bind to
exposed phospholipids in apoptotic cells [23]. The numbers of cells stained by
only PI (necrotic dead cells) or only annexin V-FITC (apoptotic dead cells)
were counted and expressed as a percentage of the total cell number.
2.4. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blotting
Whole membrane fractions (40 Ag) prepared from sub-confluent and
confluent LLC-PK1 cells were applied to the SDS-polyacrylamide gel. Proteins
were blotted onto a PVDF membrane and incubated for 60 min with an anti-
SGLT1 antibody followed by a peroxidase-conjugated anti-rabbit IgG. Finally,
the blots were stained with ECL Western Blotting Detection Regents from
Amersham Biosciences (Buckinghamshire, UK).
2.5. Extraction of LLC-PK1 cells with detergent solution
Confluent monolayers were rinsed three times with ice-cold PBS.
Extractions were performed by overlaying the cells with 1 ml of CSK-1 buffer
(0.5% Triton X-100, 100 mM NaCl, 10 mM Tris–HCl, pH 7.4, and 300 mM
sucrose) containing a protease inhibitor cocktail (Sigma) plus 1 mM
phenylmethylsulfonyl fluoride for 30 min at 4 -C on a gentle rocking platform.
The extract was completely collected (Triton X-100 soluble fraction) and the
residue (Triton X-100 insoluble fraction) was dissolved in a lysis buffer (1%
Triton X-100, 150 mM NaCl, 1 mM EDTA, 20 mM Tris–HCl, pH 7.4, 0.1%
SDS) containing protease inhibitors. These fractions were dissolved in sample
buffer for SDS-PAGE. The protein concentration was measured using a protein
assay kit (Bio-Rad Laboratories, CA) with bovine serum albumin as the
standard.
2.6. Measurement of [14C]-AMG uptake
Cells were grown to confluent densities on 24-well plates. Methyl a-
glucopyranoside (AMG) was used as non-metabolic substrate of SGLT1. [14C]-
AMG uptake was assayed by incubating in a modified Hank’s balanced salt
solution (HBSS) containing 0.1 mM unlabeled AMG, 0.5 ACi/ml [14C]-AMG
(PerkinElemer Life and Analytical Sciences, Boston, MA), 137 mM NaCl, 5
mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 10 mM HEPES (pH 7.4). After
incubation for 30 min at 37 -C, the solution was aspirated quickly and washed
with ice-cold HBSS without [14C]-AMG four times. The cells were solubilized
with 0.5 N NaOH and aliquots were taken to determine the radioactivity and
protein concentration.
2.7. Immunofluorescence microscopy
The cells grown on a cover glass were washed twice with PBS
supplemented with 0.5 mM CaCl2 and 0.5 mM MgCl2 prior to fixation with
10% formalin for 15 min at room temperature. The cells were then
permeabilized with 0.2% Triton X-100 for 15 min, and incubated with PBS
containing 5% skim milk (blocking solution) for 30 min. Incubation with the
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dilution 1/100) or the anti-endothelial nitric oxide synthase (eNOS) antibody
(BIOMOL, Plymouth Meeting, PA) for 16 h at 4 -C was followed by washing
three times with PBS, and they were then incubated for 90 min with the
TexasRed-labeled anti-rabbit IgG (EY Laboratories, San Mateo, CA) in a
blocking solution (dilution 1/100). Immunolabeled cells were visualized on the
LSM 510 confocal microscope set with the appropriate filter for TexasRed (543
nm excitation and 650 nm emission filter). Images were further processed using
Adobe Photoshop (Adobe System, Inc., San Jose, CA).
2.8. Measurement of intracellular ROS, RNS and nitric oxide
productions
The intracellular formations of superoxide anion, peroxynitrite, and nitric
oxide (NO) were detected using the fluorescent probes OxyBURST Green
H2DCFDA, H2DCFDA (Molecular Probes, Eugene, OR) and DAF-2 DA
(Daiichi Chemistry, Osaka, Japan), respectively. The cells grown on 96-well
plates were incubated with HBSS containing 5 AM OxyBURST Green
H2DCFDA, 20 AM H2DCFDA, or 5 AM DAF-2DA for 30 min at 37 -C.
After washing twice with HBSS, the cells were exposed to cisplatin for the
indicated periods. The fluorescence intensity of each probe was measured with
excitation at 485 nm and emission at 538 nm using a Multilabel Counter 1420
ARVOsx (Perkin Elemer Life and Analytical Sciences).
2.9. Measurement of PKC activity
PKC activity was measured with a PKC assay kit (Promega, Madison, WI).
The PepTag C1 peptide was used in the positive control assay. Cells wereFig. 1. Increases in transepithelial permeability and necrotic cell death by cisplatin. (
cisplatin (.), 100 AM phloridzin (g), or 500 AM cisplatin plus 100 AM phloridzin
measured at the indicated periods. Each TER values were normalized to the TER
ohmscm2 (n =6). *P <0.05 and **P <0.01, significantly different from control. #P
incubated with 500 AM cisplatin (.), 500 AM cisplatin plus 10 AM cytochalasin
significantly different from cisplatin alone. (C and D) Cells were cultured at sub-c
bottom culture dishes. Cells were preincubated with 500 AM cisplatin or 500 AM cis
and annexin V-FITC. The numbers of necrotic dead cells stained by only PI (C) or a
expressed as a percentage of the total cell number (n =6). NS, not significantly diffe
the value in the sub-confluent densities. ##P <0.01 significantly different from thegrown to confluent densities in 24-well plates and then exposed to cisplatin
(500 AM) for 4 h. After washing twice with PBS, cells were scraped by a rubber
policeman. After sonication, the samples were centrifuged at 1000g for 5 min
to remove the nuclear fraction. The supernatant was collected and the aliquot
was used for the PKC assay. The assay was performed according to the
manufacturer’s instructions. In this assay, activated PKC increases the
phosphorylated PepTag C1 peptides which migrate toward the anode by
agarose gel electrophoresis.
2.10. Statistics
Results are presented as meansTS.E.M. Differences between groups were
analyzed by one-way ANOVA, and corrections for multiple comparisons were
made by Tukey’s multiple comparison test. Comparisons between the two
groups were made by the Student’s t test. Significant differences were assumed
at P <0.05.
3. Results
3.1. Inhibition of cisplatin-induced cell injury by SGLT1
LLC-PK1, a well-differentiated epithelial cell line derived
from porcine proximal tubule cells [24], has been utilized as a
model system for studying the functions of polarized mono-
layer cells. Cisplatin (500 AM) decreased TER in a time-
dependent manner (Fig. 1A). The cisplatin-induced TERA) LLC-PK1 cells cultured on 24-transwell plates were incubated with 500 AM
(r). Control cells were incubated in the absence of these drugs (o). TER was
value at 0 h. The average TER value of control LLC-PK1 cells was 78.4T2.2
<0.05 and ##P <0.01, significantly different from cisplatin alone. (B) Cells were
B (r), or 500 AM cisplatin plus 100 AM phloretin (n) (n =4–6). **P <0.01,
onfluent (open columns) and confluent densities (hatched columns) on glass-
platin plus 100 AM phloridzin for the indicated periods prior to loading with PI
poptotic dead cells stained by only annexin V-FITC (D) were counted, and then
rent from the value without phloridzin. **P <0.01, significantly different from
value without phloridzin.
Fig. 2. Effects of cisplatin on SGLT1 expression and [14C]-AMG uptake. (A
Cells were cultured at sub-confluent or confluent densities. Whole membrane
fractions (40 Ag) were run on 10% SDS-polyacrylamide gels and transferred to
the PVDF membrane. The membrane was immunoblotted with the anti-SGLT1
antibody. The specific band of SGLT1 was observed at about 70 kDa. (B) Cells
were preincubated with or without 500 AM cisplatin for the indicated periods
Whole membrane fractions (40 Ag) were run on 10% SDS-polyacrylamide gels
and then blotted with the anti-SGLT1 antibody. (C) Cells were cultured at sub
confluent or confluent densities on a 24-well plate. [14C]-AMG uptake was
carried out at 37 -C for 30 min in the presence (hatched columns) or absence
(open columns) of 100 AM phloridzin (n =6). NS, not significantly differen
from the value without phloridzin. **P <0.01, significantly different from the
value in the sub-confluent densities. ##P <0.01, significantly different from the
value without phloridzin. (D) Cells were preincubated with 500 AM cisplatin
for 5 h or 24 h in the confluent densities. [14C]-AMG uptake was carried out a
37 -C for 30 min in the presence (hatched columns) or absence (open columns
of 100 AM phloridzin (n =4–6). NS, not significantly different from the value
at 0 h. **P <0.01, significantly different from the value at 0 h.
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a potent SGLT1 inhibitor. Phloridzin alone did not change the
basal TER. Phloretin, a nonselective inhibitor of SGLT and a
facilitate glucose transporter (GLUT), enhanced TER decrease
caused by cisplatin, whereas cytochalasin B, a selective GLUT
inhibitor, had no effect on TER decrease (Fig. 1B). These
results indicate that cisplatin increases in the TJ permeability
and SGLT1 partially blocks it. As shown in Fig. 1C, cisplatin
increased the number of necrotic dead cells. The degree of dead
cells in the sub-confluent densities was higher than that in the
confluent densities. Phloridzin significantly enhanced the
necrotic dead cells caused by cisplatin only in the confluent
densities. The cisplatin-induced TER decrease corresponded to
the increase in necrotic dead cells. On the other hand, the
number of apoptotic dead cells was not affected by treatment of
cisplatin and phloridzin for 5 h (Fig. 1D). Phloridzin alone did
not increase in the necrotic and apoptotic dead cells (data not
shown). These results indicate that high doses of cisplatin
increase the transepithelial permeability and necrotic dead cells
in a short period, and that SGLT1 endogenously protects cells
from the cisplatin-induced injury.
3.2. Effects of cisplatin on the expression and glucose transport
of SGLT1
After the formation of a confluent monolayer, LLC-PK1
cells form the TJ and express SGLT1 at the apical surface [25].
In western blotting, the specific band of SGLT1 appeared at
about 70 kDa in the confluent densities (Fig. 2A). Cisplatin had
no effect on SGLT1 expression for 5 h (Fig. 2B). LLC-PK1
cells also express SGLT3, but sodium-dependent glucose
transport is mainly mediated by SGLT1 [26]. Phloridzin-
sensitive [14C]-AMG uptake was significantly increased after
developing cell confluence in agreement with the expression of
SGLT1 protein (Fig. 2C). Cisplatin had no effect on [14C]-
AMG uptake for 5 h (Fig. 2D). Both SGLT1 protein expression
and [14C]-AMG uptake disappeared after 24-h treatment of
cisplatin. These results indicate that SGLT1 transports glucose
into the cells during the 5 h of cisplatin treatment in spite of the
increase in the transepithelial permeability and the glucose
uptake may be involved in the protection against cell injury
caused by cisplatin.
3.3. Increases in intracellular RNS and ROS productions by
cisplatin
Cells were loaded with DAF-2DA to measure intracellular
NO production in real-time. NO production was significantly
increased by cisplatin within 1 h and continued to rise over the
5-h period (Fig. 3A). Phloridzin has no effect on the basal and
cisplatin-induced NO production. The expression of eNOS
proteins have been reported in the renal cortex and medulla of
the rat [27], and we identified their expression in the LLC-PK1
cells by Western blotting (data not shown). The localization of
eNOS within the cells influences NO production [28]. In
immunofluorescence measurements, cisplatin translocated
eNOS from the cytosolic compartments to the plasma)
.
-
t
t
)membrane (Fig. 3B), indicating that cisplatin increased
intracellular NO production mediated via eNOS translocation.
Next, we examined the productions of superoxide anion and
peroxynitrite using OxyBURST Green H2DCFDA and
H2DCFDA, respectively. Cisplatin increased superoxide anion
and peroxynitrite productions in a time-dependent manner (Fig.
3C and D). Phloridzin enhanced cisplatin-induced peroxynitrite
production, whereas it had no effect on cisplatin-induced
superoxide anion production. The basal productions of
superoxide anion and peroxynitrite were not changed by
phloridzin alone, the same as NO production. These results
suggest that cisplatin increases in RNS and ROS productions in
a time-dependent manner and SGLT1 endogenously suppresses
the intracellular accumulation of peroxynitrite caused by
cisplatin.
3.4. Disruption of the TJ structure by cisplatin
The TJ consists of a number of proteins including occludin,
claudins, zonula occludens-1 (ZO-1), ZO-2, and cingulin
[29,30]. ZO-1 has an important role in the cross-links between
Fig. 3. Inhibition of cisplatin-induced peroxynitrite production by SGLT1. (A, C, and D) Cells were cultured at confluent densities on a 96-well plate prior to
loading with 5 AM DAF-2DA (A), 5 AM OxyBURST Green H2DCFDA (C), or 20 AM H2DCFDA (D) for 30 min at 37 -C. Then, cells were incubated with
(closed symbols) or without 500 AM cisplatin (open symbols) in the presence (triangles) or absence (circles) of 100 AM phloridzin for the indicated periods. The
fluorescence intensity was sequentially measured with excitation at 485 nm and emission at 538 nm (n =8). (B) Cells were cultured at confluent densities on a
cover glass. Then, cells were preincubated with 500 AM cisplatin or 100 AM phloridzin for the indicated periods. After fixation with formalin, the cells were
incubated with the anti-eNOS antibody prior to incubation with the TexasRed-labeled anti-rabbit IgG. Immunolabeled cells were visualized on the LSM 510
confocal microscope (Scale bar=10 Am).
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localized at the lateral surface of the plasma membrane in
LLC-PK1 cells (Fig. 4A). The localization of ZO-1 in the cell–
cell contact area was abolished by cisplatin. The cisplatin-
induced internalization of ZO-1 protein was inhibited by
N-nitro-l-arginine methyl ester (l-NAME, 100 AM), a NOS
inhibitor. The qualitative change in the ZO-1 distribution
pattern likely represents an alteration in the association of ZO-1
with the actin-based cytoskeleton. Treatment with cisplatin or
cisplatin plus l-NAME did not change the total amount of ZO-
1 (Fig. 4B). However, ZO-1 became more soluble to the Triton
X-100-containing buffer by cisplatin. l-NAME inhibited the
detergent extraction of ZO-1 caused by cisplatin. Similarly, the
decrease in TER by cisplatin was inhibited by l-NAME (Fig.
4C). These results indicate that cisplatin disrupts the TJ
structure mediated by NO production.
3.5. Effect of PKC inhibitor on cisplatin-induced injury
The atypical PKC isoform aPKC is localized at the cell
junctional complex in LLC-PK1 cells and PKC-activating
phorbol esters induce an increase in TJ permeability [31]. We
also observed that phorbol 12-myristate 13-acetate (PMA), an
activator of PKC, decreased in TER in LLC-PK1 cells (Fig.
5A). The PMA-induced TER decrease was completely blocked
by calphostin C, a PKC inhibitor. PKC inhibitors protectagainst cisplatin-induced apoptosis in LLC-PK1 cells [13],
which is associated with protection against the loss of cell–cell
contact. However, the high doses of cisplatin-induced TER
decrease were not blocked by calphostin C (Fig. 5B).
Cotreatment of cisplatin with PMA led to an additive TER
decrease. Control activated PKC increases of phosphorylated
PepTag C1 peptides which migrate toward the anode (Fig. 5C).
PepTag C1 peptides, however, migrated toward the cathode in
the control and the cisplatin-treated cells. Furthermore,
calphostin C blocked the PMA-induced internalization of
ZO-1, but did not block the cisplatin-induced internalization
of ZO-1 (Fig. 5D). These results indicate that PKC is not
involved in the disruption of the TJ structure by high doses of
cisplatin.
3.6. Involvement of peroxynitrite in cisplatin-induced injury
The toxicity of NO is enhanced by its reaction with
superoxide to form peroxynitrite, which induces lipid perox-
idation [32]. In rats treated with cisplatin, peroxynitrite has
been suggested to be involved in cisplatin-induced nephro-
toxicity, but its target is unknown [33]. To eliminate
intracellular peroxynitrite, we used two types of drugs:
5,10,15,20-tetrakis-(4-sulfonatophenyl)-porphyrinato iron (III)
(FeTPPS), a peroxynitrite decomposition catalyst, and reduced
glutathione (GSH), a peroxynitrite scavenger. The cisplatin-
Fig. 4. Effect of l-NAME on cisplatin-induced ZO-1 internalization. (A) Cells were cultured at confluent densities on a cover glass. Then, cells were preincubated
with 500 AM cisplatin for 5 h in the presence or absence of 100 AM l-NAME. After fixation with formalin, the cells were incubated with the anti-ZO-1 antibody
prior to incubation with the TexasRed-labeled anti-rabbit IgG (Scale bar=10 Am). (B) Cells were incubated with 500 AM cisplatin for 5 h in the presence or absence
of 100 AM l-NAME. Whole membrane (40 Ag), Triton X-100 soluble (80 Ag), and Triton X-100 insoluble (40 Ag) fractions were run on 7.5% SDS-polyacrylamide
gels and transferred to the PVDF membrane. The membrane was immunoblotted with the anti-ZO-1 antibody. The specific band of ZO-1 was observed at about 220
kDa. (C) Cells were incubated on 24-transwell plates for 0–5 h in the presence of 500 AM cisplatin (.) or 500 AM cisplatin plus 100 AM l-NAME (r). TER was
measured at the indicated periods (n =6). *P <0.05 and **P <0.01, significantly different from the value without l-NAME.
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inhibited by FeTPPS and GSH (Fig. 6A and B). These drugs
significantly inhibited the cisplatin-induced TER decrease
(Fig. 6C). These results are consistent with the effect of l-
NAME (Fig. 4). Furthermore, FeTPPS and GSH significantly
decreased the number of necrotic dead cells caused by
cisplatin without affecting apoptotic dead cells (Fig. 6D).
Our data suggest that peroxynitrite is a key mediator in the
high doses of cisplatin-induced TJ disruption and necrotic cell
death.
4. Discussion
In cisplatin chemotherapy, nephrotoxicity is a major adverse
effect that limits its use at higher doses to maximize its
therapeutic effect. Several mechanisms are implicated in the
dose-dependent and cumulative cisplatin-induced nephrotoxic
injury. Exposure of cells to substantially lower concentrations
(<50 AM) for several days leads to apoptosis [7–9]. On the
other hand, high concentrations of cisplatin (100–2000 AM)
lead to cell necrosis over several hours. Cisplatin actively
accumulates in proximal tubular epithelial cells [34]. However,
the mechanism by which high doses of cisplatin cause renal
damage remains unclear. In this study, we found that cisplatin
increased in the transepithelial permeability and necrotic dead
cells in LLC-PK1 cells (Fig. 1).
In proximal tubular epithelial cells, cisplatin may be
transported into the cytosol, mediated by organic cation
transporters (OCTs) [35], and then be excreted into urine,mediated by an unknown pathway. High expression levels of
OCTs can be found in the S3 segment of the proximal tubule
[36]. The epithelial cells must have a cytoprotective function
against cisplatin to excrete high doses of cisplatin. SGLT1 is
predominantly expressed in the S3 segment and reabsorbs the
remaining glucose not reabsorbed in the early proximal tubule.
In LLC-PK1 cells, SGLT1 appeared after the confluent
densities (Fig. 2). Interestingly, the protective function of cells
against high doses of cisplatin was more potent in the confluent
densities than in the sub-confluent densities (Fig. 1C). We
suggest that the function and morphology of LLC-PK1 cells are
changed by differentiation, and SGLT1 expression is partially
related to the acquisition of a protective function against
cisplatin.
Cisplatin inhibits the low-affinity SGLT (probably SGLT2)
in renal proximal tubular cells [37] and in brush border
membrane vesicles prepared from the renal cortex of animals
exposed to cisplatin in vivo [38]. The cisplatin-induced
inhibition of SGLT2 may result from a direct interaction
between cisplatin and the SGLT2 protein. In the present study,
a high affinity SGLT (SGLT1) was not inhibited by cisplatin
for at least 5 h (Fig. 2). Potdevin et al. [39] reported that
cisplatin-induced inhibition of SGLT2 could result from
covalent platinum binding to SH groups of the transporter.
The amino acid sequence of human SGLT2 is 59% identical to
that of human SGLT1 [40]. The cysteine residues of SGLT2 at
535, 546, 592, and 610 are not conserved in SGLT1. We
suggest that SGLT1 fulfills its function even under the
exposure of cells to cisplatin.
Fig. 5. Independency of PKC on the increase in transepithelial permeability by cisplatin. (A) Cells were incubated with 100 nM PMA (.) or 100 nM PMA plus 500 nM
calphostin C (r). Control cells were incubated in the absence of these drugs (o). TER was measured at the indicated periods (n =6). **P <0.01, significantly different
from control. ##P <0.01, significantly different from PMAalone. (B) Cells were incubatedwith 500 AMcisplatin (.), 500 AMcisplatin plus 500 nM calphostin C (r), or
500 AM cisplatin plus 100 nM PMA (n). TER was measured at the indicated periods (n =4–6). (C) Cells were incubated on 24-well plates for 4 h in the presence or
absence of 500 AMcisplatin. After the scraping and sonication of cells, the supernatant without the nuclear fraction was collected by centrifugation. An aliquot (100 Ag)
was used for the PKC assay. As a positive control assay, PKC (control enzyme) was added at 10 or 20 ng. (D) Cells were preincubated with 100 nM PMA, 100 nM PMA
plus 500 nM calphostin C, 500 AM cisplatin, or 500 AM cisplatin plus 500 nM calphostin C for 5 h. After fixation with formalin, the cells were incubated with the anti-
ZO-1 antibody prior to the incubation with the TexasRed-labeled anti-rabbit IgG (Scale bar=10 Am).
A. Ikari et al. / Biochimica et Biophysica Acta 1717 (2005) 109–117 115Glucose uptake is involved in the cytoprotective function
against hydrogen peroxide [41] and the inhibition of mito-
chondrial respiration [42]. The general effects of glucose may
be mediated by the uptake and subsequent intracellular
metabolism of glucose. GSH can counteract the damaging
effects of ROS and RNS. Actually, the addition of GSH
suppressed the cisplatin-induced TER decrease and ZO-1
internalization (Fig. 6). GSH is the substrate for glutathione
peroxidase, converting GSH to its oxidized disulfide form
(GSSG). GSH can be regenerated from GSSG by glutathione
reductase, which uses NADPH produced mainly by glucose
metabolism via the pentose phosphate cycle. One of the
cytoprotective mechanisms of SGLT1 may be the reduction of
RNS by glucose metabolism. Phloridzin enhanced the cisplat-
in-induced TER decrease (Fig. 1), whereas it did not enhance
the cisplatin-induced NO and superoxide anion productions
(Fig. 3A and D). Furthermore, the inhibition of GLUT by
cytochalasin B did not affect the cisplatin-induced TER
decrease. These results suggest that glucose transported by
SGLT1 suppresses peroxynitrite production or incites perox-
ynitrite metabolite without inhibiting cisplatin-induced NO and
superoxide anion productions.
NO is able to react with superoxide to produce peroxynitrite,
which is a powerful oxidant, being more reactive than its
precursors. The administration of NG-nitro-l-arginine methyl
ester, an inhibitor of NOS, reduced nephrotoxicity and alsodecreased the content of blood urea nitrogen in cisplatin-treated
rats [43]. Cisplatin-induced nephrotoxicity was attenuated by
FeTPPS, suggesting the involvement of peroxynitrite [33]. It is,
however, unknown how peroxynitrite damages the proximal
tubular cells. We found that the cisplatin-induced TER decrease
was inhibited by l-NAME, FeTPPS, and GSH (Figs. 4 and 6).
Furthermore, these drugs prevented the cisplatin-induced
disruption of ZO-1 localization at TJ and changes in the
detergent solubility of ZO-1. Peroxynitrite produced by
cisplatin must be involved in the disruption of TJ structure.
In cultured epithelial cells, the disassembly of ZO-1 from TJ
strands correlates with disruption of the epithelial barrier
[44,45]. In calcium switch experiments, low extracellular
calcium leads to a decline in TER and the internalization or
diffusion of TJ proteins [46]. ZO-1 becomes more soluble with
detergent-containing solutions, suggesting a weakening of the
interactions between ZO-1 and the cytoskeleton. Oxidative
stress also leads to the decline of TER and the disruption of
ZO-1 localization at TJ [47]. In cisplatin-induced apoptosis,
PKC is suggested to be involved in the loss of adherens
junctions in LLC-PK1 cells [13]. There is a possibility that high
doses of cisplatin disrupt TJ structure mediated via PKC
activation. However, cisplatin did not activate PKC and the
cisplatin-induced TER decrease was not inhibited by the PKC
inhibitor (Fig. 5). Furthermore, cotreatment of cisplatin with
PMA accelerated the TER decrease compared with cisplatin
Fig. 6. Inhibition of cisplatin-induced TJ disruption by peroxynitrite inhibitors. (A) Cells were incubated with 500 AM cisplatin for 5 h in the presence or absence of
50 AM FeTPPS or 100 AM GSH. After fixation with formalin, the cells were incubated with the anti-ZO-1 antibody prior to incubation with the TexasRed-labeled
anti-rabbit IgG (Scale bar=10 Am). (B) Cells were incubated with 500 AM cisplatin for 5 h in the presence or absence of 50 AM FeTPPS or 100 AM GSH. Whole
membrane (40 Ag), Triton X-100 soluble (80 Ag), and Triton X-100 insoluble (40 Ag) fractions were run on 7.5% SDS-polyacrylamide gels and transferred to the
PVDF membrane. The membrane was immunoblotted with the anti-ZO-1 antibody. (C) Cells were incubated with 500 AM cisplatin (.), 500 AM cisplatin plus 50
AM FeTPPS (r), or 500 AM cisplatin plus 100 AM GSH (n). TER was measured at the indicated periods (n =6). *P <0.05 and **P <0.01, significantly different
from cisplatin alone. (D) Cells were preincubated with 500 AM cisplatin for 5 h in the presence or absence of 50 AM FeTPPS or 100 AMGSH prior to loading with PI
and annexin V-FITC. Necrotic dead cells (hatched columns) and apoptotic dead cells (open columns) were expressed as a percentage of the total cell number (n =6).
**P <0.01, significantly different from control. ##P <0.01, significantly different from cisplatin alone.
A. Ikari et al. / Biochimica et Biophysica Acta 1717 (2005) 109–117116alone. Clarke et al. [31] reported that PKC activation leads to a
decline in TER, but it did not change the detergent solubility of
ZO-1. However, ZO-1 became more soluble to the Triton X-
100-containing solution by cisplatin (Fig. 4). We suggest that
PKC is not involved in high doses of cisplatin-induced TJ
injury.
In conclusion, high doses of cisplatin cause nephrotoxicity
mediated via a different pathway from that in apoptosis.
Cisplatin increases intracellular peroxynitrite production,
resulting in the disruption of TJ construction in renal proximal
tubular epithelial cells. The disruption of barrier function and
the loss of polarity must lead to tissue injury. SGLT1 expressed
in the S3 segment partially suppresses cisplatin-induced
peroxynitrite production and protects cells from cisplatin-
induced nephrotoxicity. In the animal model, tubular injury
plays a central role in the reduction of the glomerular filtration
rate in acute tubular necrosis. In cisplatin chemotherapy, the
elimination of peroxynitrite may be useful in arresting the
development of nephrotoxicity.
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